Valeant Pharmaceuticals International’s wholly owned subsidiary Bausch + Lomb has received approval from the US Food and Drug Administration (FDA) for its new drug application (NDA) for the once-daily glaucoma treatment Vyzulta.

Vyzulta is indicated to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Valeant Pharmaceuticals International chairman and CEO Joseph Papa said: “With today’s approval of Vyzulta, our customers and their patients with glaucoma now have a new treatment option that can help provide consistent and sustained IOP lowering, the only modifiable risk factor that can help slow down the progression of the disease.

“We expect to make this new advancement available for those who suffer with glaucoma before the end of the year.”

“We expect to make this new advancement available for those who suffer with glaucoma before the end of the year.”

Following topical administration, the once-daily monotherapy with a dual mechanism of action, Vyzulta, works by metabolising into two moieties, latanoprost acid.

Conjunctival hyperemia, eye irritation, eye pain and instillation site pain are the most common ocular adverse events that occur.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In patients with glaucoma, damage to the trabecular meshwork, through which the majority of the aqueous humor passes, can lead to reduced drainage and finally elevated IOP.

Vyzulta was licensed on a global basis to Bausch + Lomb from Nicox, which will receive $17.5m from Bausch + Lomb and will make a $15m payment to Pfizer as part of a previous license agreement.

Nicox chairman and CEO Michele Garufi said: “Vyzulta represents the first FDA-approved therapy developed through our proprietary NO-donating research platform.”